Evommune (EVMN) Equity Average (2024 - 2026)

Evommune (EVMN) has 3 years of Equity Average data on file, last reported at $255.1 million in Q1 2026.

• Quarterly Equity Average rose 268.65% year-over-year to $255.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $255.1 million (up 268.65% YoY) and the FY2025 annual result came in at $30.7 million, changed N/A from the prior year.
• Equity Average rose to $255.1 million in Q1 2026 per EVMN's latest filing, from $11.2 million in the prior quarter.
• Across five years, Equity Average topped out at $255.1 million in Q1 2026 and bottomed at -$170.7 million in Q3 2025.
• The 3-year median for Equity Average is -$133.4 million (2024), against an average of -$37.8 million.
• The widest annual swing landed in 2025, when Equity Average jumped 108.41%; it then surged 268.65% in 2026.
• Tracing EVMN's Equity Average over 3 years: stood at -$133.4 million in 2024, then soared by 108.41% to $11.2 million in 2025, then surged by 2174.38% to $255.1 million in 2026.
• Per Business Quant, the three latest EVMN Equity Average figures stand at $255.1 million (Q1 2026), $11.2 million (Q4 2025), and -$170.7 million (Q3 2025).

Peer Comparison